Subscribe free

Intestine and Lower Gastrointestinal Tract ·

Watch-and-Wait yields favorable outcomes in rectal cancer patients

Broad implementation of Watch-and-Wait for rectal cancer in the Netherlands shows promising results. Among 1,080 patients, 45% achieved clinical complete response post-treatment, with a three-year organ preservation rate of 76%. The study also found a 23% incidence of local regrowth and an overall survival rate of 97%. Notably, no significant differences in regrowth or metastases arose between the study’s cohorts, indicating successful application of treatment protocols in high-volume hospitals.

Multicenter Study by Geubels BM, Grotenhuis BA (…) Beets GL et 5 al. in Br J Surg

© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

read the whole article in Br J Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →